BBVXF
BANCO BILBAO VIZCAYA ARGENTARIA, S.A.
$23.17
+2.84%
No data for this timeframe.
Vol
SEC Reports20
Recent Activity
Jun 1, 2026
SEC
BBVA disclosed weekly buyback activity under its Third Tranche share repurchase program for May 25-29, 2026, purchasing
6-K — Impact 2/10
May 26, 2026
SEC
BBVA disclosed the execution of its third share buyback tranche, purchasing 6,475,290 shares between May 18-22, 2026, fo
6-K — Impact 3/10
May 18, 2026
SEC
BBVA disclosed the execution of its third tranche share buyback program, purchasing shares worth €218.5 million between
6-K — Impact 3/10
Analyst Ratings
6Strong Buy
13Buy
11Hold
1Sell
0Strong Sell
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
20 SEC filing reports analyzed. Sentiment: 4 bullish, 0 bearish, 0 mixed, 16 neutral. Avg impact: 3.8/10.
NEUTRAL
6-K
2/10
BBVA disclosed weekly buyback activity under its Third Tranche share repurchase program for May 25-2
Jun 1, 2026
NEUTRAL
6-K
3/10
BBVA disclosed the execution of its third share buyback tranche, purchasing 6,475,290 shares between
May 26, 2026
NEUTRAL
6-K
3/10
BBVA disclosed the execution of its third tranche share buyback program, purchasing shares worth €21
May 18, 2026
BULLISH
6-K
5/10
Fitch Ratings upgraded BBVA's long-term issuer default rating to A from A- and long-term deposit rat
May 12, 2026
NEUTRAL
6-K
2/10
BBVA disclosed the execution of its third share buyback tranche, purchasing shares between May 6-8,
May 11, 2026
NEUTRAL
6-K
3/10
BBVA is issuing $1.25 billion of 4.968% senior non-preferred fixed-rate notes due 2031, with net pro
May 8, 2026
NEUTRAL
6-K
5/10
BBVA is pricing a $1 billion Series 16 AT1 CoCo perpetual preferred securities offering with a 7.125
May 8, 2026
NEUTRAL
424B5
3/10
BBVA is issuing $1.25 billion of 4.968% senior non-preferred fixed-rate notes due 2031, with net pro
May 4, 2026
NEUTRAL
424B5
5/10
BBVA is issuing $1 billion in Series 16 perpetual non-cumulative contingent convertible preferred se
May 4, 2026
NEUTRAL
6-K
2/10
BBVA's Board of Directors approved changes to the composition of its Audit, Remuneration, and Risk a
Apr 30, 2026
NEUTRAL
6-K
4/10
BBVA announced a third tranche of its share buyback program, authorizing up to EUR 1,460 million to
Apr 30, 2026
BULLISH
6-K
7/10
BBVA reported strong Q1 2026 results, with net attributable profit up 10.8% YoY on a constant basis
Apr 30, 2026
BULLISH
6-K
7/10
BBVA reported Q1 2026 net attributable profit of €2,989 million, up 10.8% YoY (14.1% at constant FX)
Apr 30, 2026
BULLISH
6-K
7/10
BBVA reported strong Q1 2026 results, with net attributable profit up 10.8% YoY to €2,989 million, d
Apr 30, 2026
NEUTRAL
424B5
3/10
BBVA is issuing an undisclosed amount of senior non-preferred fixed-rate notes due 2031. The proceed
Apr 30, 2026
NEUTRAL
424B5
3/10
BBVA is offering an undisclosed amount of Series 16 Non-Step-Up Non-Cumulative Contingent Convertibl
Apr 30, 2026
NEUTRAL
6-K
2/10
BBVA filed an amended version of its corporate bylaws via a Form 6-K. The changes are routine corpor
Apr 29, 2026
NEUTRAL
6-K
2/10
BBVA announced it will present its 1Q 2026 financial results on April 30, 2026, via a webcast. This
Apr 22, 2026
NEUTRAL
6-K
4/10
Banco Bilbao Vizcaya Argentaria (BBVA) completed the acquisition of 52.8 million shares, representin
Apr 17, 2026
NEUTRAL
6-K
4/10
BBVA announced it has received updated Minimum Requirement for own funds and Eligible Liabilities (M
Apr 15, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 61% buy across 31 analysts — 6 strong buy, 13 buy, 11 hold, 1 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $10.0B | 9.4% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $42.9B | 3.7% | — |
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $9.8B | 12.7% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $41.3B | 11.9% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 13 | 11 | 1 | 0 | 61% | |
| May 1, 2026 | 5 | 14 | 11 | 2 | 0 | 59% | |
| Apr 1, 2026 | 5 | 15 | 8 | 2 | 0 | 67% | |
| Mar 1, 2026 | 5 | 15 | 8 | 2 | 0 | 67% | |
| Feb 1, 2026 | 6 | 13 | 7 | 3 | 0 | 66% | |
| Jan 1, 2026 | 6 | 13 | 6 | 2 | 0 | 70% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.